Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Current Proteomics is a distinguished journal dedicated to the dynamic field of proteomics, offering researchers and professionals a platform to disseminate innovative findings and comprehensive reviews. Published by Bentham Science Publishers Ltd, this journal caters to a global audience and serves as an essential resource for students, academics, and industry experts interested in advances in biochemistry and molecular biology. With an ISSN of 1570-1646 and an E-ISSN of 1875-6247, the journal has established itself in various research categories, achieving a Q4 ranking in both Biochemistry and Molecular Biology as of 2023. While the impact factor and H-index data are not specified, its Scopus ranking reflects a competitive position in its fields, with percentiles in the 12th to 16th range. Although not an open-access journal, Current Proteomics is vital for fostering ongoing dialogue and collaboration in proteomic research, encouraging contributions that explore cutting-edge methodologies and applications. Researchers are invited to share their insights and contribute to this evolving discipline, thus enhancing the collective understanding of proteomics within the scientific community.

Journal of Proteomics, published by Elsevier, is an esteemed peer-reviewed journal dedicated to advancing research in the field of proteomics, with broad implications for biochemistry and biophysics. Established in 2008, the journal has continuously evolved, embracing innovative methodologies and technologies that facilitate protein analysis from a variety of biological systems. With its current standing in the Q2 category for both biochemistry and biophysics as of 2023, it is recognized as a significant contributor to scientific literature. The journal publishes original research articles, reviews, and methodological advancements, providing invaluable insights for researchers, professionals, and students alike. Although it does not offer open access, the journal remains a crucial platform for disseminating knowledge that informs various applications, ranging from drug development to disease understanding. As it converges towards 2024, the Journal of Proteomics continues to solidify its role in shaping the future of proteomic research through rigorous scientific inquiry and innovation.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

Cancer Informatics, published by SAGE PUBLICATIONS LTD, is a leading open-access journal dedicated to the integration of computational techniques and cancer research. Since its inception in 2005, this journal has become a vital resource for researchers, professionals, and students interested in the intersection of informatics and oncology. With an E-ISSN of 1176-9351 and a focus on the innovative application of data analysis in cancer research, Cancer Informatics serves to disseminate critical findings that aid in understanding cancer biology and enhancing treatment modalities. Recognized in the Q3 category for both Cancer Research and Oncology according to the 2023 metrics, it currently holds a Scopus ranking of #246 in Medicine _ Oncology and #172 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, indicating its contribution to ongoing research in these fields. This journal not only supports open access to scientific findings but also aims to foster collaboration among interdisciplinary scholars worldwide, making it an essential platform for advancing the field of cancer informatics through cutting-edge research and innovative methodologies.

Metabolomics is a distinguished academic journal published by SPRINGER, dedicated to advancing the field of metabolomics and its applications in various biochemistry-related domains. With a focus on innovative research in biochemistry, clinical biochemistry, and endocrinology, diabetes, and metabolism, this journal holds a significant position, being categorized in the Q2 quartile across multiple fields in the 2023 rankings. The journal is indexed with notable metrics: ranking 73rd in Endocrinology, Diabetes and Metabolism and 38th in Clinical Biochemistry on Scopus, demonstrating its impactful contribution to the scientific community. Established in 2005, Metabolomics provides a vital platform for researchers, professionals, and students to access high-quality research, facilitating advancements in our understanding of metabolic processes and their implications in health and disease. Access options include subscription-based reading, ensuring that valuable insights are available to a broad audience across the globe.

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.